Do you have anxiety? Our biotechnology stems from over a decade of research and development, and has been used in pharmaceutical applications by some of the World’s largest pharmaceutical companies.
GCANRx is setting the bar for improved onset of action, dosing accuracy, enhanced efficacy, and safety in the delivery of cannabinoids.
GCANRx has the exclusive worldwide license for PharMedica’s Eluting Transmucosal Patch Platform (ETP) for non-invasive drug delivery in the Cannabis field.
The company holds the rights to new delivery technologies using a bio-adhesive, adjustable dose, and fully dissolvable, non-irritant patch, which provides for a needle free, intra-oral systemic drug delivery. The conveyance technology is designed to accelerate and enhance the delivery and bioavailability of medicines and cannabis actives when compared to traditional methods of enteral administration.
The transmembrane functionality enables needle-free, transmucosal drug delivery, administering the medicine directly into the blood system while bypassing the digestive and hepatic systems, thereby increasing the bioavailability and lowering the dose required to achieve desired therapeutic effects.
News 
Market Data 
Discover 
AI
